{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:35:22Z","timestamp":1793090122332,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105593","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T06:03:48Z","timestamp":1789279428000},"page":"105593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting intracellular immune regulatory molecules for cancer immunotherapy in solid tumors"],"prefix":"10.1016","volume":"227","author":[{"given":"Chunyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105593_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ebiom.2017.04.024","article-title":"Diacylglycerol Kinase \u03b6 Limits Cytokine-dependent expansion of CD8+ T Cells with broad antitumor capacity","volume":"19","author":"Andrada","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105593_bib2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00262-018-2154-8","article-title":"Diacylglycerol kinase \u03b1 inactivation is an integral component of the costimulatory pathway that amplifies TCR signals","volume":"67","author":"Arranz-Nicol\u00e1s","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105593_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006007","article-title":"Targeting Cbl-b in cancer immunotherapy","volume":"11","author":"Augustin","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105593_bib4","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41586-023-06575-7","article-title":"The PTPN2\/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity","volume":"622","author":"Baumgartner","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105593_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004244","article-title":"Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity","volume":"10","author":"Bernard","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105593_bib6","unstructured":"Boehringer Ingelheim, 2025. A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT04147234 (accessed 9.1.26)."},{"key":"10.1016\/j.critrevonc.2026.105593_bib7","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.4049\/jimmunol.1402254","article-title":"Deficiency of MALT1 Paracaspase Activity Results in Unbalanced Regulatory and Effector T and B Cell Responses Leading to Multiorgan Inflammation","volume":"194","author":"Bornancin","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib8","article-title":"HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1\/2 trial results","volume":"7","author":"Braun","year":"2026","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105593_bib9","first-page":"S626","article-title":"1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors","volume":"34","author":"Calvo","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib10","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.chembiol.2015.07.017","article-title":"Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors","volume":"22","author":"Canning","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s42003-026-09579-x","article-title":"CISH, a key intracellular checkpoint, in comparison and combination to existing and emerging cancer immune checkpoints","volume":"9","author":"Cano","year":"2026","journal-title":"Commun. Biol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/lifemedi\/lnad019","article-title":"Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy","volume":"2","author":"Carelock","year":"2023","journal-title":"Life Med."},{"key":"10.1016\/j.critrevonc.2026.105593_bib13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2767-9764.CRC-24-0407","article-title":"Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors","volume":"5","author":"Carneiro","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105593_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abc6612","article-title":"Emerging roles of PLC\u03b31 in endothelial biology","volume":"14","author":"Chen","year":"2021","journal-title":"Sci. Signal."},{"key":"10.1016\/j.critrevonc.2026.105593_bib15","article-title":"Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2016.00130","article-title":"Diacylglycerol kinases in T cell tolerance and effector function","volume":"4","author":"Chen","year":"2016","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202400920","article-title":"HPK1 dysregulation-associated NK cell dysfunction and defective expansion promotes metastatic melanoma progression","volume":"11","author":"Choi","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2026.105593_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012064","article-title":"Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade","volume":"13","author":"Ciccone","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105593_bib19","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ni.3470","article-title":"CIS is a potent checkpoint in NK cell-mediated tumor immunity","volume":"17","author":"Delconte","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.molmed.2015.12.004","article-title":"Targeting MALT1 proteolytic activity in immunity, inflammation and disease: good or bad?","volume":"22","author":"Demeyer","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105593_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.2585","article-title":"A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors","volume":"42","author":"Deva","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1215-2","article-title":"Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy","volume":"570","author":"DiPilato","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105593_bib23","article-title":"CRISPR-Cas9 knockout of DGK\u03b1\/\u03b6 improves the anti-tumor activities of TAG-72 CAR-T cells in ovarian cancer","volume":"33","author":"Evtimov","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib24","doi-asserted-by":"crossref","first-page":"22002","DOI":"10.1021\/acs.jmedchem.4c01930","article-title":"Discovery of PF-07265028, a selective small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1) for the treatment of cancer","volume":"67","author":"Gallego","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105593_bib25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd2783","article-title":"Unleashing the therapeutic potential of NOD-like receptors","volume":"8","author":"Geddes","year":"2009","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105593_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-\u03b3: teammate or opponent in the tumour microenvironment?","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib27","unstructured":"Hanna, G.J., 2025. Duvelisib Plus Docetaxel In Recurrent\/Metastatic HNSCC [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT05057247 (accessed 9.2.26)."},{"key":"10.1016\/j.critrevonc.2026.105593_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1078-0432.CCR-24-2262","article-title":"Duvelisib with docetaxel for patients with anti\u2013PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma","volume":"31","author":"Hanna","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105593_bib29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/14796694.2024.2441107","article-title":"Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors","volume":"21","author":"Harrington","year":"2025","journal-title":"Futur. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib30","doi-asserted-by":"crossref","first-page":"S684","DOI":"10.1016\/j.annonc.2024.08.1066","article-title":"1007P Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study","volume":"35","author":"Harrington","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell. Res."},{"key":"10.1016\/j.critrevonc.2026.105593_bib32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.celrep.2018.09.012","article-title":"The kinase activity of hematopoietic progenitor kinase 1 Is essential for the regulation of T cell function","volume":"25","author":"Hernandez","year":"2018","journal-title":"Cell. Rep."},{"key":"10.1016\/j.critrevonc.2026.105593_bib33","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","article-title":"Eganelisib, a first-in-class PI3Kg inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105593_bib34","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.cell.2026.06.001","article-title":"The cGAS-STING pathway: mechanism and medical implications","volume":"189","author":"Hooftman","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105593_bib35","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-24-3691","article-title":"JAB-3312, a potent allosteric SHP2 inhibitor that enhances the efficacy of RTK\/RAS\/MAPK and PD-1 blockade therapies","volume":"31","author":"Kang","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105593_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-70060-8","article-title":"A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance","volume":"17","author":"Karunaraj","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105593_bib37","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2025.07.010","article-title":"Heterozygous loss of MAP4K1 causes immune dysregulation by amplifying T-cell responses","volume":"156","author":"Kaustio","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","article-title":"Decoding Toll-like receptors: recent insights and perspectives in innate immunity","volume":"57","author":"Kawai","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105593_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.2661","article-title":"Systemic third generation allosteric STING agonist CRD3874-SI, a novel immunotherapy, in patients with advanced solid tumors: Results from a single-agent phase I study","volume":"44","author":"Kelly","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nri1750","article-title":"SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond","volume":"6","author":"Koretzky","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nri1750","article-title":"SLP76 and SLP65: Complex regulation of signalling in lymphocytes and beyond","volume":"6","author":"Koretzky","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1853","article-title":"DGK\u03b1\/\u03b6 inhibition lowers the TCR affinity threshold and potentiates antitumor immunity","volume":"9","author":"Kureshi","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105593_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005845","article-title":"Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets","volume":"11","author":"Laletin","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105593_bib44","doi-asserted-by":"crossref","first-page":"S864","DOI":"10.1016\/j.annonc.2025.08.2183","article-title":"1553P A phase I dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma","volume":"36","author":"Lavingia","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib45","article-title":"STING agonist JMKX000197 infusion in patients with malignant pleural effusion: Preliminary results from a prospective phase Ib study","volume":"44","author":"Li","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib46","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1038\/s41467-023-40170-8","article-title":"A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity","volume":"14","author":"Liang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105593_bib47","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT073","article-title":"Abstract CT073: A first-in-human study of oral TNO155 (batoprotafib) alone and in combination with EGF816 (nazartinib) in adult patients with advanced solid tumors","volume":"85","author":"Lin","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105593_bib48","article-title":"CRISPR\/Cas9-mediated SHP-1-knockout T cells combined with simvastatin enhances anti-tumor activity in humanized-PDX HCC model","volume":"28","author":"Liu","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2026.105593_bib49","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nri1731","article-title":"Immunity by ubiquitylation: A reversible process of modification","volume":"5","author":"Liu","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(25)00083-X","article-title":"Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial","volume":"26","author":"Lou","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib51","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41568-025-00894-9","article-title":"Opportunities and challenges of targeting cGAS\u2013STING in cancer","volume":"26","author":"Lu","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105593_bib52","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib53","series-title":"SITC 39th Annual Meeting (SITC 2024)","article-title":"1310 Peripheral blood and tumor gene expression as biomarkers and potential predictors of clinical outcome with HST-1011, an oral CBL-B inhibitor","author":"Luke","year":"2024"},{"key":"10.1016\/j.critrevonc.2026.105593_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non\u2013small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105593_bib55","series-title":"SITC 40th Annual Meeting (SITC 2025)","article-title":"424 Pharmacodynamic profiling of diacylglycerol kinase inhibition reveals immune activation and synergy with PD1 blockade in preclinical tumor models","author":"Melidosian","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105593_bib56","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105593_bib57","doi-asserted-by":"crossref","first-page":"S872","DOI":"10.1016\/j.annonc.2025.08.2201","article-title":"1571P REVERT study: A phase Ib\/IIa study to assess the efficacy of the first-in-class RIPK2 inhibitor OPM-101 in patients with advanced melanoma resistant to anti\u2013PD-1\u2013based regimens","volume":"36","author":"Michielin","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib58","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.trecan.2025.01.008","article-title":"Targeting PI3K\u03b3 in cancer","volume":"11","author":"Mognol","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105593_bib59","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/2767-9764.CRC-22-0461","article-title":"Combination of itacitinib or parsaclisib with pembrolizumab in patients with advanced solid tumors: a phase I study","volume":"3","author":"Munster","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105593_bib60","doi-asserted-by":"crossref","unstructured":"Naing, A., 2025. First-in-human, phase 1 study of BGB-26808 (hematopoietic progenitor kinase 1 [HPK1] inhibitor) \u00b1 tislelizumab (TIS; anti-PD-1) in advanced solid tumors (STs) [WWW Document]. URL https:\/\/beonemedaffairs.com\/us\/congress-resources\/esmo-2025\/first-in-human-phase-1-study-of-bgb-26808-hematopoietic-progenitor-kinase-1-hpk1-inhibitor-\u00b1-tislelizumab-tis-anti-pd-1-in-advanced-solid-tumors-sts\/ (accessed 9.1.26).","DOI":"10.1016\/j.annonc.2025.08.2194"},{"key":"10.1016\/j.critrevonc.2026.105593_bib61","doi-asserted-by":"crossref","first-page":"S627","DOI":"10.1016\/j.annonc.2023.09.2172","article-title":"1033P First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors","volume":"34","author":"Naing","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib62","article-title":"Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment","volume":"12","author":"O\u2019Connell","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105593_bib63","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41573-022-00538-9","article-title":"The expanding role for small molecules in immuno-oncology","volume":"21","author":"Offringa","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105593_bib64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib65","unstructured":"Oncology Pipeline and Clinical Development | BeOne Medicines [WWW Document], n.d. URL https:\/\/beonemedicines.com\/science\/pipeline\/ (accessed 7.20.26)."},{"key":"10.1016\/j.critrevonc.2026.105593_bib66","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1084\/jem.20150304","article-title":"Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance","volume":"212","author":"Palmer","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105593_bib67","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.medj.2022.07.008","article-title":"Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade","volume":"3","author":"Palmer","year":"2022","journal-title":"Med"},{"key":"10.1016\/j.critrevonc.2026.105593_bib68","series-title":"SITC 38th Annual Meeting (SITC 2023)","article-title":"741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies","author":"Papadopoulos","year":"2023"},{"key":"10.1016\/j.critrevonc.2026.105593_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113610","article-title":"Uncovering the individual immunotherapeutic roles of PTPN1 and PTPN2 in T cells during dual inhibition","volume":"28","author":"Perez-Quintero","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2026.105593_bib70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib71","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-3789","article-title":"Abstract 3789: INCB177054: A novel, potent, orally bioavailable DGK\u03b1\/\u03b6 dual inhibitor enhances T-cell function and demonstrates potent antitumor activity","volume":"85","author":"Ren","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105593_bib72","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41577-020-0352-z","article-title":"Functional categories of immune inhibitory receptors","volume":"20","author":"Rumpret","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib73","doi-asserted-by":"crossref","first-page":"S675","DOI":"10.1016\/j.annonc.2024.08.1050","article-title":"991O First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors","volume":"35","author":"Sanborn","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.276pe38","article-title":"Activation of T cells: Releasing the brakes by proteolytic elimination of Cbl-b","volume":"2","author":"Schmitz","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.critrevonc.2026.105593_bib75","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-23-A097","article-title":"Abstract A097: HBI-2438, HUYABIO selective KRASG12C inhibitor with BBB penetration, inhibited tumor growth in a metastatic brain model as single agent and also displayed synergy in combination with HBI-2376 (HUYABIO SHP2 inhibitor) in a CRC PDX model","volume":"22","author":"Shojaei","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105593_bib76","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-1041","article-title":"Abstract 1041: HBI-2376, HUYABIO clinical stage SHP2 inhibitor, possess robust in vitro potency and in vivo efficacy in several preclinical tumor models carrying KrasG12C or EGFR mutations","volume":"82","author":"Shojaei","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105593_bib77","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ni1416","article-title":"Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell\u2013mediated immune responses","volume":"8","author":"Shui","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib78","first-page":"302","article-title":"Severe defects in immunity and hematopoiesis caused by SHP-1 protein- tyrosine-phosphatase deficiency. Trends Biotechnol","volume":"15","author":"Shultz","year":"1997"},{"key":"10.1016\/j.critrevonc.2026.105593_bib79","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","article-title":"Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies","volume":"38","author":"Si","year":"2020","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105593_bib80","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2326-6066.CIR-19-0690","article-title":"Inhibition of SHP-1 expands the repertoire of antitumor t cells available to respond to immune checkpoint blockade","volume":"8","author":"Snook","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105593_bib81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s10020-022-00475-8","article-title":"Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction","volume":"28","author":"Song","year":"2022","journal-title":"Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105593_bib82","unstructured":"Squibb, B.-M., 2026. A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | ClinicalTrials.gov [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT05407675 (accessed 7.20.26)."},{"key":"10.1016\/j.critrevonc.2026.105593_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2018.11.002","article-title":"Regulation of immune responses by E3 ubiquitin ligase Cbl-b","volume":"340","author":"Tang","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib84","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nri2338","article-title":"Multifunctional roles for MALT1 in T-cell activation","volume":"8","author":"Thome","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115683","article-title":"RIPK2 inhibitors for disease therapy: Current status and perspectives","volume":"259","author":"Tian","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105593_bib86","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.436","article-title":"Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma","volume":"39","author":"Tomczak","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib87","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105593_bib88","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: the path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib89","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1158\/0008-5472.CAN-09-4076","article-title":"Cbl-b and itch: Key regulators of peripheral T-cell tolerance","volume":"70","author":"Venuprasad","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105593_bib90","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163873","article-title":"Hematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia","volume":"133","author":"Wang","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105593_bib91","article-title":"Combination of golidocitinib (a JAK1 inhibitor) with anti\u2013PD-1 antibody to improve tumor response and patient quality of life: Preliminary results from an ongoing JACKPOT 33 study","volume":"44","author":"Wang","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh1892","article-title":"DGK\u03b1\/\u03b6 inhibitors combine with PD-1 checkpoint therapy to promote T cell\u2013mediated antitumor immunity","volume":"15","author":"Wichroski","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105593_bib93","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2326-6066.CIR-25-0156","article-title":"Discovery of BMS-986408, a First-In-Class Dual DGK\u03b1 and DGK\u03b6 Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies","volume":"13","author":"Wichroski","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105593_bib94","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1172\/JCI59492","article-title":"T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice","volume":"121","author":"Wiede","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105593_bib95","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/ng0693-124","article-title":"Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene","volume":"4","author":"Wo Tsui","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2026.105593_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202411454","article-title":"An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti-Solid Tumor Immunity","volume":"37","author":"Yao","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.critrevonc.2026.105593_bib97","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41392-024-01826-z","article-title":"Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities","volume":"9","author":"Yin","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105593_bib98","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.it.2011.04.007","article-title":"PKC-\u03b8 function at the immunological synapse: prospects for therapeutic targeting","volume":"32","author":"Zanin-Zhorov","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib99","article-title":"Initial results from a phase I study of the SHP2 inhibitor GH21 as monotherapy in patients with advanced solid tumors","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib100","article-title":"A phase I\/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumors","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib101","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41423-022-00957-z","article-title":"CIS controls the functional polarization of GM-CSF-derived macrophages","volume":"20","author":"Zhang","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib102","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.tcb.2024.10.008","article-title":"Targeting SHP1 and SHP2 to suppress tumors and enhance immunosurveillance","volume":"35","author":"Zhao","year":"2025","journal-title":"Trends Cell. Biol."},{"key":"10.1016\/j.critrevonc.2026.105593_bib103","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S2213-2600(25)00258-9","article-title":"Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1\/2a trial","volume":"14","author":"Zhong","year":"2026","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.critrevonc.2026.105593_bib104","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell. Stem Cell."},{"key":"10.1016\/j.critrevonc.2026.105593_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011180","article-title":"Cbl-b inhibitor NX-1607 activates MAPK\/ERK signaling pathway and enhances T-cell activation","volume":"13","author":"Zhu","year":"2025","journal-title":"J. Immunother. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:47:13Z","timestamp":1793087233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":105,"alternative-id":["S1040842826004804"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105593","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting intracellular immune regulatory molecules for cancer immunotherapy in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105593"}}